Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Frevecitinib
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Clears KN-002 IND for Asthma by Kinaset Therapeutics
Details : KN-002 (frevecitinib) is a JAK1/2/3 inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of patients with asthma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 29, 2025
Lead Product(s) : Frevecitinib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Frevecitinib
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Kinaset Therapeutics Shares Positive Data from Phase 1b KN-002 Study at ATS 2024
Details : KN-002 is a pan-JAK inhibitor formulated as a dry powder for delivery via the non-invasive oral inhalation. It is being evaluated in a Phase 1 for mild to severe asthma and those with COPD.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 21, 2024
Lead Product(s) : Frevecitinib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KN-002
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Single and Multiple Ascending Dose Study of KN-002
Details : KN-002 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 16, 2021
Lead Product(s) : KN-002
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VR588
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Vectura Ltd
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : This agreement provides an opportunity for Vectura to realise value from its historical research and investment in VR588, whilst expanding its CDMO development services portfolio by supporting the product's further development with Kinaset.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 30, 2020
Lead Product(s) : VR588
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Vectura Ltd
Deal Size : Undisclosed
Deal Type : Licensing Agreement